Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
108 hedge funds and large institutions have $3.27B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 24 reducing their positions, and 14 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 24
38% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $10.3M
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
1% more funds holding
Funds holding: 107 → 108 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less capital invested
Capital invested by funds: $4.25B → $3.27B (-$981M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.7M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$12M |
| 4 |
Morgan Stanley
New York
|
+$7.94M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$13.8M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$7.1M |
| 3 |
Bank of New York Mellon
New York
|
-$5.64M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.17M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.68M |
CERE Hedge Fund Activity: Q2 2022 in Review
108 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q2 2022, worth a combined $3.27B — down 23% from $4.25B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CERE positions and 14 closed out — a net gain of 4 holders — while 51 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $21M. The largest seller was Alkeon Capital Management, cutting an estimated $13.8M.
- 108 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q2 2022, up from 107 in Q1 2022.
- Funds reported $3.27B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q2 2022, down 23% quarter-over-quarter.
- 18 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q2 2022 and 14 closed out, a net change of +4 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q2 2022 was BlackRock, an estimated $21M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q2 2022 was Alkeon Capital Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2022.